Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple myeloma.

Kenneth C Anderson1, John D Shaughnessy, Bart Barlogie

  • 1Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Hematology. American Society of Hematology. Education Program
|November 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging.

Blood advances·2025
Same author

Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice.

Haematologica·2025
Same author

Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols: A Secondary Analysis of 3 Clinical Trials.

JAMA oncology·2025
Same author

Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma.

Blood advances·2025
Same author

A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma.

Haematologica·2024
Same author

Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma.

American journal of hematology·2024
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

This update offers new insights into multiple myeloma (MM) biology, diagnosis, and treatment. Advances include gene expression profiling for classification, stem cell transplantation, understanding bone disease mechanisms, and targeting the tumor microenvironment for novel therapies.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Multiple myeloma (MM) is a complex plasma cell malignancy with significant impact on bone health and patient survival.
  • Understanding the molecular underpinnings and tumor microenvironment interactions is crucial for developing effective treatments.

Purpose of the Study:

  • To provide a comprehensive update on the latest advancements in the biology, diagnosis, prognosis, and treatment of multiple myeloma.
  • To highlight novel therapeutic targets and strategies based on recent research findings.

Main Methods:

  • Gene expression profiling of patient MM samples to classify disease stages.
  • Review of high-dose therapy and stem cell transplantation (autologous and allogeneic) outcomes.
  • Investigation of mechanisms underlying MM bone disease and bone marrow microenvironment interactions.

Related Experiment Videos

Main Results:

  • Development of a developmental stage-based classification of MM using gene expression profiling.
  • Insights into the pathogenesis of MM bone disease, including osteoclast activation and cell interactions.
  • Elucidation of the bone marrow microenvironment's role in MM cell growth, survival, and drug resistance.

Conclusions:

  • Gene expression profiling offers clinical utility for understanding MM mechanisms and identifying therapeutic targets.
  • Advances in stem cell transplantation and understanding MM bone disease pave the way for novel therapeutic approaches.
  • Targeting MM cell-host interactions presents a promising strategy for future MM therapies.